A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Solid Tumors

Treatments: Drug: Brivanib

Study type: Interventional

Funder types: Industry

Identifiers

NCT00390936

CA182-012

Details and patient eligibility

About

The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.

Enrollment: 13 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients must have measurable disease
• Documented failure to standard therapies exist, or which are determined to be inappropriate by the investigator
• ECOG PS: 0-1

Exclusion criteria

• Subjects with centrally located squamous cell carcinoma of the lung

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

13 participants in 1 patient group

1

No Intervention group

Description:

4 dosages

Treatment:

Drug: Brivanib